Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 …
YY Janjigian, A Kawazoe, Y Bai, J Xu, S Lonardi… - The Lancet, 2023 - thelancet.com
Background Evidence for the efficacy of combined PD-1 and HER2 blockade with
chemotherapy on progression-free and overall survival in HER2-positive gastro …
chemotherapy on progression-free and overall survival in HER2-positive gastro …
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Background Addition of trastuzumab to first-line chemotherapy improves overall survival in
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …
Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT)
T Van Den Ende, NC De Clercq… - Clinical Cancer …, 2021 - AACR
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients
with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated …
with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated …
Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model
Inactivation of the tumor suppressor genes tumor protein p53 (TP53) and cyclin-dependent
kinase inhibitor 2A (CDKN2A) occurs early during gastroesophageal junction (GEJ) …
kinase inhibitor 2A (CDKN2A) occurs early during gastroesophageal junction (GEJ) …
Essential updates 2019/2020: Perioperative and surgical management of gastric cancer
T Irino, S Matsuda, N Wada… - Annals of …, 2021 - Wiley Online Library
Perioperative and surgical management of gastric cancer have been changing as pivotal
phase II trials and landmark phase III trials offer new insights to the existing knowledge. The …
phase II trials and landmark phase III trials offer new insights to the existing knowledge. The …
[HTML][HTML] Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
MPG Dings, AP van der Zalm, S Bootsma… - Cell Reports …, 2022 - cell.com
Neoadjuvant chemoradiotherapy (nCRT) improves outcomes in resectable esophageal
adenocarcinoma (EAC), but acquired resistance precludes long-term efficacy. Here, we …
adenocarcinoma (EAC), but acquired resistance precludes long-term efficacy. Here, we …
[HTML][HTML] Esophagectomy or total gastrectomy for Siewert 2 gastroesophageal junction (GEJ) adenocarcinoma? A registry-based analysis
SK Kamarajah, AW Phillips, EA Griffiths, L Ferri… - Annals of surgical …, 2021 - Springer
Backgrounds Due to a lack of randomized and large studies, the optimal surgical approach
for Siewert 2 gastroesophageal junctional (GEJ) adenocarcinoma remains unknown. This …
for Siewert 2 gastroesophageal junctional (GEJ) adenocarcinoma remains unknown. This …
Preoperative chemoradiation versus chemotherapy in gastroesophageal junction adenocarcinoma
Background The incidence of lower esophageal and gastroesophageal junction
adenocarcinoma has sharply increased over the past several decades and is a serious …
adenocarcinoma has sharply increased over the past several decades and is a serious …
Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy
X Wang, MJ Allen, O Espin-Garcia, C Suzuiki… - The …, 2024 - academic.oup.com
Background The incidence of esophageal and gastric carcinoma (GEC) in elderly patients is
increasing, yet patients≥ 75 years have historically been underrepresented in clinical trials …
increasing, yet patients≥ 75 years have historically been underrepresented in clinical trials …
[HTML][HTML] Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
W Mansoor, HT Arkenau, M Alsina, K Shitara… - Gastric Cancer, 2021 - Springer
Background Patients with advanced gastroesophageal junction cancer (GEJC) have poor
survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers …
survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers …